Brachytherapy can now reduce treatment time for breast cancer

A new form of treatment, Brachytherapy can now reduce treatment time for breast cancers.
The technique involves the insertion of radioactive implants directly into the cancer cell tissue.
As for treatment, breast-conserving surgery followed by radiation therapy and hormonal treatment/chemotherapy depending on the type of cancer is the standard care for newly diagnosed breast cancer in elderly women.
‘External radiation therapy lasting 4-6 weeks involves 21 to 31 sittings. But, with use of brachytherapy techniques, we can reduce treatment time to one week. Accelerated Partial Breast Irradiation (APBI) and HDR Brachytherapy are the techniques used in these women,’ said a doctor, Manish Chandra.
This technique, however, comes with strict selection criteria; it is prescribed for women around 50 years or above when the tumour size is less than 3 cm provided there is a non-involvement of axiliary nodes. If planned properly, it can be done in a cancer-oriented set up during primary surgery or post-surgically.
‘But, it’s advisable to perform it immediately after surgery when the patient is still under anesthesia. The main advantage of this technique is that it helps in the direct visualisation of the tumour bed which in turn helps in the precise placement of brachytherapy catheters,’ added the doctor.
Performing this technique post-surgically demands a sound clinical judgment and should be done under USG guidance. The technique reduces overall treatment period by 3-4 weeks and eliminates lots of stress in elderly women leading to better treatment compliance and good result.
Unfortunately, this modality is underutilized owing to physician preferences as well as due to lack of training. Use of breast brachytherapy is strongly encouraged and trained physicians should offer this as a standard of care.
Meanwhile, Manish Chandra finds the trend in breast-conserving surgery very encouraging. In the olden days, in women over 60 years decision was often taken by male members of the family. But, these days most patients are involved in pre-treatment counseling.
‘Recently, we treated a 77-year-old woman who didn’t want to settle for anything other than this new technique. Luckily, she fulfilled the selection criteria and today she’s leading a happy and healthy life,’ said the oncologist.
For, cancer cases are on the rise across India, particularly, in urban areas. A study by Indian Council of Medical Research (ICMR) predicts India could be hit by 17.3 lakh new cancer cases down next two years.
Thus, by 2020 the country will have 2.5 million people living with cancer while cancer-related mortality could touch an astounding 8.8 lakh. But, what particularly worries the medical experts and healthcare providers in the country is the alarming rise in the number of breast cancer cases.
Studies also reveal breast cancer globally affects around one in 28 women in their early 30s. This, however, peaks in women in the age group of 50 to 64. Latest Indian data show one in 22 women develop breast cancer and of the two diagnosed, one dies.
Source:http://www.dnaindia.com/health/report-brachytherapy-can-now-reduce-treatment-time-for-breast-cancer-2635408

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more